Get the Stockscreener App
59.48
0.93%
-0.56
After Hours:
59.41
-0.07
-0.12%
Dexcom Inc stock is traded at $59.48, with a volume of 5.53M.
It is down -0.93% in the last 24 hours and down -4.40% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$60.04
Open:
$60.54
24h Volume:
5.53M
Relative Volume:
1.21
Market Cap:
$22.95B
Revenue:
$4.66B
Net Income/Loss:
$836.30M
P/E Ratio:
28.42
EPS:
2.093
Net Cash Flow:
$1.08B
1W Performance:
+0.27%
1M Performance:
-4.40%
6M Performance:
+0.34%
1Y Performance:
-25.90%
1-Day Range:
$58.98
$61.00
1-Week Range:
$56.72
$62.85
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
59.48 | 23.17B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Alert from law firm tagged to Dexcom withdrawn - marketscreener.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time - Investing.com
3 Reasons Analysts Love DexCom - MarketBeat
Dexcom to Host Investor Day on May 14, 2026 - The Joplin Globe
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
JPMorgan prices $345K DexCom‑linked callable notes | JPM Prospectus Summary - Stock Titan
PFA Pension Forsikringsaktieselskab Acquires New Stake in DexCom, Inc. $DXCM - MarketBeat
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise - MSN
Should DexCom’s Margin Gains and Expanded Coverage Require Action From DexCom (DXCM) Investors? - Yahoo Finance
Canaccord Genuity Adjusts Price Target on DexCom to $100 From $95, Maintains Buy Rating - Moomoo
Dexcom, Inc. Q1 2026 Financial Results: Strong Revenue, Earnings, and Forward-Looking Statements - Minichart
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Faces Potential Headwinds in 2026, but Expanding Reimbursement Offers Long-Term Prospects - Morningstar
DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says - marketscreener.com
JPMorgan Adjusts DexCom Price Target to $65 From $75 - marketscreener.com
DexCom, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:DXCM) 2026-05-01 - Seeking Alpha
DexCom, Inc. (NASDAQ:DXCM) Q1 2026 Earnings Call Transcript - Insider Monkey
DexCom, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook - Yahoo Finance
DexCom Inc (NASDAQ:DXCM): A GARP Stock with Affordable Growth and Strong Fundamentals - ChartMill
Barclays Adjusts Price Target on DexCom to $67 From $72, Maintains Underweight Rating - marketscreener.com
Leerink Partners Adjusts Price Target on DexCom to $80 From $95, Maintains Outperform Rating - marketscreener.com
Bernstein Adjusts Price Target on DexCom to $77 From $83, Maintains Outperform Rating - marketscreener.com
Bernstein SocGen lowers DexCom stock price target on valuation By Investing.com - Investing.com Canada
Raymond James Adjusts Price Target on DexCom to $81 From $83, Maintains Strong Buy Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on DexCom to $80 From $82, Maintains Buy Rating - marketscreener.com
TD Cowen Adjusts Price Target on DexCom to $75 From $84, Maintains Buy Rating - marketscreener.com
Citigroup Adjusts Price Target on DexCom to $79 From $84, Maintains Buy Rating - marketscreener.com
Mizuho cuts DexCom stock price target to $75 on valuation reset - Investing.com
HB Wealth Management LLC Cuts Stake in DexCom, Inc. $DXCM - MarketBeat
BTIG Remains Bullish on DexCom, Inc. (DXCM) - Insider Monkey
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Expansions - GuruFocus
DexCom Inc (DXCM) Stock Price, Trades & News - GuruFocus
DexCom Q1 2026 slides: margin expansion accelerates, guidance raised By Investing.com - Investing.com South Africa
DexCom (DXCM) Reports Strong Q1 2026 Revenue Growth Driven by Pr - GuruFocus
MSN Money - MSN
Is It Too Late to Buy DexCom Inc (DXCM) After 3.5% Rally? GF Value Says Undervalued - GuruFocus
Is DexCom (DXCM) 45.7% Undervalued After Q1 2026 Earnings Beat? - GuruFocus
Is It Too Late to Buy DexCom Inc (DXCM) After 3.5% Rally? GF Val - GuruFocus
DexCom (DXCM) Q1 2026 Earnings Transcript - The Motley Fool
Earnings call transcript: DexCom beats Q1 2026 forecasts, stock rises By Investing.com - Investing.com Australia
DexCom Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: DexCom beats Q1 2026 forecasts, stock rises - Investing.com
Transcript : DexCom, Inc., Q1 2026 Earnings Call, Apr 30, 2026 - marketscreener.com
DexCom Q1 2026 Earnings Call Transcript - Benzinga
DexCom, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
DexCom (DXCM) Q1 Earnings and Revenues Top Estimates - Yahoo Finance Singapore
Dexcom reaffirms full-year forecast after topping quarterly estimates - marketscreener.com
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):